Dr Jordan Conway is a Postdoctoral Researcher at the Melanoma Institute Australia and an Honorary Associate Lecturer at The University of Sydney. His research focuses on how distinct tumour microenvironments, particularly in visceral sites such as the liver, shape tumour–immune interactions, drive immune evasion, and confer resistance to immunotherapy.

Dr Conway integrates spatial biology, translational immunology, and advanced in vivo modelling to uncover mechanisms of resistance and identify new therapeutic strategies. He has developed novel murine models that replicate organ-specific features of melanoma and employs advanced imaging techniques, including MRI, to monitor tumour dynamics and treatment responses in real time.

At MIA, Dr Conway plays a central role in the Neoadjuvant Immunotherapy Translational Research Platform (NeoPlatform), coordinating multi-disciplinary workflows, supervising junior researchers and PhD students, and contributing to biomarker and endpoint analysis across several investigator-led clinical trials. His expertise includes multiplex immunohistochemistry, mass cytometry (CyTOF), and advanced spatial profiling.

Dr Conway has authored multiple peer-reviewed publications, including first-author work in the Journal for ImmunoTherapy of Cancer (JITC), and has presented his research at international meetings such as AACR, SMR, and EACR. With dual expertise in preclinical model development and clinical trial integration, his goal is to deliver insights that guide future personalised immunotherapy strategies and contribute to MIA’s vision of zero deaths from cancer.